AI-powered clinical trial site feasibility market seen topping $4.38 billion by 2030

The market for AI-driven clinical trial site feasibility is projected to jump from $1.53 billion in 2025 to $1.89 billion in 2026, as drug developers turn to data tools to speed site selection and reduce trial delays. The Business Research Company says the category could reach $4.38 billion by 2030, with North America leading and Asia-Pacific growing fastest.

Why it matters: - AI-powered site feasibility tools are becoming a key part of clinical trial planning as sponsors try to shorten development timelines and cut the risk of site failures. - The market's growth reflects rising pressure to choose trial sites faster and with better data, especially as trials become more complex and global.

What happened: - The Business Research Company released its Artificial Intelligence (AI)-Driven Clinical Trial Global Market Report 2026, covering market size, trends, and forecasts for 2026-2035. - The report values the AI-powered clinical trial site feasibility market at $1.53 billion in 2025. - The report projects the market will reach $1.89 billion in 2026, a 23.6% compound annual growth rate. - The report forecasts the market will grow to $4.38 billion by 2030, at a 23.3% compound annual growth rate. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - AI-powered clinical trial site feasibility platforms use algorithms to evaluate and select trial sites. - These tools analyze large datasets to predict site performance and patient enrollment potential. - The technology is designed to speed decision-making and reduce trial delays. - The market's recent expansion is tied to more complex clinical trial protocols, cost pressure to shorten drug development timelines, and broader use of predictive analytics. - Future growth drivers include wider adoption of decentralized clinical trials, faster site activation, greater use of real-world evidence, expansion of AI-enabled trial planning platforms, and a stronger focus on managing trial risk. - Anticipated trends include AI-powered site selection models, predictive patient recruitment analytics, integration of real-world data, cloud-based feasibility solutions, and trial performance forecasting. - Increasing clinical trial volume is a major growth factor for the market. - In April 2025, the Multidisciplinary Digital Publishing Institute reported that interventional clinical trials listed on ClinicalTrials.gov reached 404,637. - The report covers major regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The company also provided a free sample report and a full market report.

Between the lines: - The forecast suggests AI is moving from a supporting analytics tool to a core operational layer in clinical development. - The regional split points to established research infrastructure in North America and faster technology adoption in Asia-Pacific as two different growth paths for the market. - The emphasis on real-world evidence and decentralized trials signals a shift toward more distributed, data-rich study designs.

What's next: - The market is expected to keep expanding through 2030 as clinical trial sponsors adopt more automation in site selection and enrollment forecasting. - The strongest demand should come from organizations that need faster site activation and more reliable patient recruitment planning. - More cloud-based and AI-enabled trial planning platforms are likely to enter the market as vendors compete on forecasting accuracy and workflow speed.